Biognosys

At Biognosys, we believe that we can dramatically improve human health by deciphering the biological complexity of diseases. By providing access to the proteome on all levels, we enable life science researchers and drug hunters to unlock true discoveries. We push the boundaries of what is possible with our proteomics solutions to help usher in a new age of bioengineering and precision medicine. When we look at the proteome differently, we envision a better world! To learn more about our vision, mission, and values, watch our new corporate video and visit: http://ow.ly/nlPM50KNHhT #Proteomics #MassSpectrometry #DrugDiscovery #DrugDevelopment #PrecisionMedicine

Heading to #ASCOGI2025 in San Francisco? We're happy to share our collaboration poster with Nexosome Oncology! In the poster session, they'll unveil latest findings on early-stage colorectal cancer (CRC) detection from patient derived extra cellular vesicles (EVs). 🔬 Using our unbiased #TrueDiscovery® proteomics platform, extracellular vesicles from patient #plasma were analyzed to uncover novel biomarkers for pre-cancerous and Stage 1 CRC. Key Insights: ✅ Identified 336+ biomarkers for Stage 0 and 493+ for Stage 1 CRC patients. ✅ Machine learning pinpointed 5 pre-cancer and 34 Stage 1 with >99% accuracy. This innovative approach paves the way for sensitive, non-invasive analytical workflow to address unmet needs in early stage colorectal cancer detection. 📍 Learn more about our #proteomics solutions: https://lnkd.in/dMaQ-ybT #Oncology #MassSpectrometry

📢 #NewBlog Alert: Decoding Protein Modifications with #Spectronaut📢 Our latest blog entry dives into Spectronaut's automated PTM normalization feature, simplifying PTM analysis. Discover how it streamlines workflows by normalizing background proteins for accurate and reliable #PTMQuantification. See what the buzz is about! 📖 Read the full story here: https://lnkd.in/dHmBmRna

🚀 Explore our latest news article: 2024 Literature Highlights Dive into the groundbreaking innovations of #Spectronaut! This year's highlights showcase how Spectronaut is transforming proteomics with advancements in #DIAanalysis, #immunopeptidomics, and proteogenomics—setting new benchmarks in data quality, scalability, and precision. 🌟Discover how Spectronaut is driving innovation, redefining possibilities in #BiomedicalResearch, and shaping the future of #proteomics. 📖Don't miss out—read the full article now: https://lnkd.in/dMetYHy4!  

As the year ends, we want to thank you for your support and interest in Biognosys. We hope this holiday season brings you joy and precious moments with your loved ones. May the new year be filled with happiness, health, and groundbreaking proteomics discoveries! In the holiday spirit, we've made a donation to One Tree Planted, a non-profit organization dedicated to global reforestation. Their efforts help restore forests, support critical biodiversity habitats, and make a positive social impact around the world. We look forward to achieving great things together and pushing the boundaries of proteomics in 2025!

Last Friday, the Biognosys team gathered for a holiday celebration at Hiltl Akademie in the heart of Zurich.🎉 The evening was filled with joy, laughter, and festive spirit as we enjoyed a delightful flying dinner. 🍽️✨ Here's to more wonderful moments together as we wrap up the year and look forward to an exciting 2025 full of new #proteomics discoveries! 🌟 #CompanyEvent #ChristmasParty #TeamSpirit

🌟 Unleash the Power of #Immunopeptidomics 🌟 Advancing #immunooncology and #autoimmune therapies starts with understanding the #immunopeptidome. Overcome challenges like sensitivity and reproducibility with our cutting-edge #TrueDiscovery® immunopeptidome profiling services. 🎯Key Applications 👉MHC Class I & II peptide profiling for disease-specific discoveries 👉Targeted quantitation of immunopeptides 👉Neoantigen discovery & immunomodulation profiling 👉Autoantigen profiling in autoimmune disorders Partner with us to redefine precision #immunotherapy. 📖 Learn more: https://lnkd.in/ebuzaXsC #MassSpectrometry #Proteomics #Immunology

🤝 We're delighted to spotlight our partnership with IonOpticks, a leader in chromatography solutions. Xavier Perronnet, CEO of IonOpticks, shares: "Collaborating with the world-class team at Biognosys has been incredibly rewarding. Developing a column that meets their rigorous performance and quality standards has been an exciting project, aligning with our ambition to deliver the best-performing columns for the expanding market." Together, we're advancing #proteomics research and driving innovation. 📄 Read the full press release: https://lnkd.in/d7-Hq_hH #MassSpectrometry #LCMS #Innovation #Collaboration

🚨 New on LinkedIn! 🚨 🌟 As we are reflecting on 2024, we're pleased to share the latest article by our CTO, Lukas Reiter! In this thought-provoking piece, Lucas dives into: 🔬 Opportunities and challenges in mass spectrometry-driven proteomics. ⚙️ How cutting-edge technology drives innovation while maintaining consistency. 🎉 Highlights from our annual workflow release, which boosts the power of #TrueDiscovery®, #TrueSignature®, and #TrueTarget® services. Don't miss this behind-the-scenes outlook at how we're advancing #proteomics to empower groundbreaking discoveries. 👉 Read the article here! https://lnkd.in/dGm3RBGp #MassSpectrometry #Innovation #DrugDiscovery #Year2024

📣 Partnership Announcement! 🤝 We are pleased to announce our partnership with IonOpticks! We've integrated a custom chromatography column exclusively developed for our #proteomics contract research (CRO) services. 🚀 This innovation boosts our workflows, ensuring maximum sensitivity, depth of coverage, and reproducibility, significantly enhancing performance of our #TrueDiscovery®, #TrueSignature®, and #TrueTarget® services platforms. This partnership perfectly aligns with our commitment to delivering high-quality CRO services. 👉 Read the full press release to learn more: https://lnkd.in/d7-Hq_hH #Innovation #MassSpectrometry #Workflowupdate